TEGA Therapeutics

Executive Summary

TEGA Therapeutics is a privately held biotechnology company founded in 2018 and headquartered in San Diego, California. The company leverages glycobiology to develop novel therapeutics based on recombinantly produced heparan sulfate (HS) variants. Its platform enables the creation of well-defined, non-animal-derived HS molecules with potential applications in anticoagulation, viral inhibition, anti-inflammatory diseases, and particularly as enzyme replacement therapies for lysosomal storage disorders. By engineering HS with precise sulfation patterns, TEGA aims to overcome the limitations of animal-derived heparin and address unmet needs in rare diseases and broader therapeutic areas. The company is advancing its lead program targeting a lysosomal storage disease, with preclinical studies demonstrating proof-of-concept. TEGA is actively working toward an Investigational New Drug (IND) application and expects to initiate first-in-human trials within the next 12–18 months. Its HS platform also holds promise for partnering in antiviral and anti-inflammatory indications. While still in early stages, TEGA's differentiated technology and experienced management team position it as a potentially attractive opportunity in the glycobiology space. Near-term value inflection points include regulatory filings, preclinical data milestones, and potential financing rounds.

Upcoming Catalysts (preview)

• Q2 2027IND submission for lead program in lysosomal storage disease60% success
• H1 2027Presentation of preclinical efficacy data at major scientific conference (e.g., ASGCT, SSIEM)70% success
• Q4 2026Series A or B financing round to fund IND-enabling studies50% success